Download arglaes in the or

A RG L A E S IN THE OR
A N T I M I C R O B I A L S I lV e R T E C H N O L O GY
Argl aes
A n t i m i c r o b i a l S i lv e r T e c h n o l o g y
MA
EXT R A
XORB
MS
C7
1
1
P
2E
Argl aes
A n t i m i c r o b i a l S i lv e r T e c h n o l o g y
Medline Industries, Inc. first introduced Arglaes® silver
The financial implications of this new payment
dressings in 1997, and we’ve continued to be one of
provision are tremendous. The table below lists the
the leaders in silver antimicrobial technology ever since.
additional costs of several different types of surgical site
We’re more confident than ever before that Arglaes
infections.3
Su rgica l Site In fection
In ciden ce An d Cost
Reported
Cases
(FY2007)
Additional Cost
Per Hospital
Stay
Mediastinitis after
CABG
69
$299,237
Total knee replacement
539
$63,135
Laparoscopic
gastric bypass &
gastroenterostomy
208
$180,142
3
$66,355
estimates that approximately 290,000 surgical site
deaths per year are associated with these infections.1
As of October 1, 2008, the Centers for Medicare &
Medicaid Services (CMS) has ceased reimbursing
facilities at a higher diagnostic category for a number
of preventable hospital-acquired conditions (HACs).2
Surgical site infections following coronary artery
bypass graft, bariatric surgery and certain orthopedic
procedures are included in the 10 categories of
conditions that were selected for the HAC payment
provision.2
mortality risk. In addition, the length of post-operative
stays nearly tripled. The same study concluded that
ARGLAES FILM MSC9314
(with Maxorb Extra MSC7112EP)
contracted a SSI over patients who did not. 4
infection prevention strategy.
infections (SSIs) occur each year.1 Roughly 8,000 patient
infections were associated with a nearly 4 times greater
hospital expenses nearly doubled for patients who
silver film can be a valuable ally in your surgical site
The Centers for Disease Control and Prevention (CDC)
In a study involving elderly patients, surgical site
Infection
Ligation and stripping of
varicose veins
Overall, patients who contract a SSI are 5 times more
likely to be readmitted to the hospital.5
Programs that can limit the rate of SSIs can substantially
decrease mortality rates and the economic burden on
hospitals.5
It has never been more critical that SSIs are prevented.
There is now a tangible cost for not implementing
aggressive infection prevention strategies. This is why
it has never been a better time to protect yourself and
your patients by choosing Arglaes.
References
1 Centers for Disease Control and Prevention. Surgical Site
Infection – FAQ. Available at: http://www.cdc.gov/ncidod/
dhqp/FAQ_SSI.html#D. Accessed January 28, 2009.
2 Centers for Medicare & Medicaid Services. HospitalAcquired Conditions. Available at: http://www.cms.hhs.
gov/HospitalAcqCond/06_Hospital-Acquired_Conditions.
asp#TopOfPage. Accessed January 28, 2009.
3 Centers for Medicare & Medicaid Services. Medicare
Program; Proposed Changes to the Hospital Inpatient
Prospective Payment Systems and Fiscal Year 2009 Rates;
Proposed Changes to Disclosure of Physician Ownership in
Hospitals and Physician Self-Referral Rules; Proposed Collection of Information Regarding Financial Relationships Between
Hospitals and Physicians; Proposed Rule. Federal Register.
2008;73(84):23552-59.
4 Kaye KS, Anderson DJ, Sloane R et al. The effect of surgical
site infection on older operative patients. Journal of the
American Geriatrics Society. 2009;57(1)46-54.
5 Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton
DJ. The impact of surgical-site infections in the 1990s:
attributable mortality, excess length of hospitalization, and
extra costs. Infection Control and Hospital Epidemiology. 1999
Nov;20(11):722-4.
6 Gonzalez VR, Segal CG, Tillmann C, Houston H, Pruitt V.
Changing clinical practice to reduce sternal surgical site infections (S-SSI) in open bypass surgery. Presented at the Association for Professionals in Infection Control and Epidemiology,
Inc. (APIC) conference in Seattle, Wash., June, 2001.
7 Independent study preformed by Wickham Laboratories
Limited, Hampshire, England.
2
3
Argl aes
A n t i m i c r o b i a l S i lv e r T e c h n o l o g y
MA
EXT R A
XORB
MS
C7
1
1
P
2E
Argl aes
A n t i m i c r o b i a l S i lv e r T e c h n o l o g y
Medline Industries, Inc. first introduced Arglaes® silver
The financial implications of this new payment
dressings in 1997, and we’ve continued to be one of
provision are tremendous. The table below lists the
the leaders in silver antimicrobial technology ever since.
additional costs of several different types of surgical site
We’re more confident than ever before that Arglaes
infections.3
Su rgica l Site In fection
In ciden ce An d Cost
Reported
Cases
(FY2007)
Additional Cost
Per Hospital
Stay
Mediastinitis after
CABG
69
$299,237
Total knee replacement
539
$63,135
Laparoscopic
gastric bypass &
gastroenterostomy
208
$180,142
3
$66,355
estimates that approximately 290,000 surgical site
deaths per year are associated with these infections.1
As of October 1, 2008, the Centers for Medicare &
Medicaid Services (CMS) has ceased reimbursing
facilities at a higher diagnostic category for a number
of preventable hospital-acquired conditions (HACs).2
Surgical site infections following coronary artery
bypass graft, bariatric surgery and certain orthopedic
procedures are included in the 10 categories of
conditions that were selected for the HAC payment
provision.2
mortality risk. In addition, the length of post-operative
stays nearly tripled. The same study concluded that
ARGLAES FILM MSC9314
(with Maxorb Extra MSC7112EP)
contracted a SSI over patients who did not. 4
infection prevention strategy.
infections (SSIs) occur each year.1 Roughly 8,000 patient
infections were associated with a nearly 4 times greater
hospital expenses nearly doubled for patients who
silver film can be a valuable ally in your surgical site
The Centers for Disease Control and Prevention (CDC)
In a study involving elderly patients, surgical site
Infection
Ligation and stripping of
varicose veins
Overall, patients who contract a SSI are 5 times more
likely to be readmitted to the hospital.5
Programs that can limit the rate of SSIs can substantially
decrease mortality rates and the economic burden on
hospitals.5
It has never been more critical that SSIs are prevented.
There is now a tangible cost for not implementing
aggressive infection prevention strategies. This is why
it has never been a better time to protect yourself and
your patients by choosing Arglaes.
References
1 Centers for Disease Control and Prevention. Surgical Site
Infection – FAQ. Available at: http://www.cdc.gov/ncidod/
dhqp/FAQ_SSI.html#D. Accessed January 28, 2009.
2 Centers for Medicare & Medicaid Services. HospitalAcquired Conditions. Available at: http://www.cms.hhs.
gov/HospitalAcqCond/06_Hospital-Acquired_Conditions.
asp#TopOfPage. Accessed January 28, 2009.
3 Centers for Medicare & Medicaid Services. Medicare
Program; Proposed Changes to the Hospital Inpatient
Prospective Payment Systems and Fiscal Year 2009 Rates;
Proposed Changes to Disclosure of Physician Ownership in
Hospitals and Physician Self-Referral Rules; Proposed Collection of Information Regarding Financial Relationships Between
Hospitals and Physicians; Proposed Rule. Federal Register.
2008;73(84):23552-59.
4 Kaye KS, Anderson DJ, Sloane R et al. The effect of surgical
site infection on older operative patients. Journal of the
American Geriatrics Society. 2009;57(1)46-54.
5 Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton
DJ. The impact of surgical-site infections in the 1990s:
attributable mortality, excess length of hospitalization, and
extra costs. Infection Control and Hospital Epidemiology. 1999
Nov;20(11):722-4.
6 Gonzalez VR, Segal CG, Tillmann C, Houston H, Pruitt V.
Changing clinical practice to reduce sternal surgical site infections (S-SSI) in open bypass surgery. Presented at the Association for Professionals in Infection Control and Epidemiology,
Inc. (APIC) conference in Seattle, Wash., June, 2001.
7 Independent study preformed by Wickham Laboratories
Limited, Hampshire, England.
2
3
THE t e c h n o lo gy b e h i n d A r g l a e s
S-SSI RATES AT 3 MONTHS6
22% REDUCTION
6
5.4%
5
Medline has long been an innovator in silver dressing
In one study, a hospital realized a 22 percent decrease
technology, with more unique application methods
in its overall sternal SSI (S-SSI) rate after implementing
to utilize the antibacterial properties of ionic silver
Arglaes Film as the standard of care for sternotomy
in wound dressings than any other company. When
incisions. Sternal SSI rates for the following nine-month
Arglaes Film was introduced in 1997, it was the first
period showed a continuation in the study results. 6
2
Arglaes is available as a transparent film dressing, with
1
6
Without
Arglaes
4.6%
With
Arglaes
4
3.6%
3
antimicrobial, sustained-release dressing on the market.
Arglaes technology utilizes ionic silver to create an
and without an alginate pad, as well as a powder. The
environment that is hostile to bacteria and fungi yet
film has a high moisture vapor transmission rate (MVTR)
completely non-cytotoxic. Arglaes’ sustained-activity
to help maintain an ideal moist wound environment.
0
FY99 Total
Jan-Mar
1999
ARGLAES FILM MSC9169
being applied
Jan-Mar
2000
ionic silver maintains full efficacy for up to seven days.
Sustained Release7
10,000,000
1,000,000
100,000
10,000
1,000
100
Numbers of
10
viable bacteria
I l l us t rat ion of C on t r ol l e d - Rel ea se Polymers
Arglaes provides an antimicrobial barrier for up to seven days. Silver ions are released at a constant rate, providing a barrier
that inhibits the growth of new bacteria and helps prevent the migration of already-existing bacteria.
24 HRS
48 HRS
7 DAYS
Staphylococcus aureus
Greater than 90% reduction in viable
bacterial numbers after 48 hours.
nil
0
10,000,000
1,000,000
100,000
10,000
1,000
100
Numbers of
10
viable bacteria
48
72
96
288
nil
10,000,000
1,000,000
100,000
10,000
1,000
100
Numbers of
10
viable bacteria
48
72
96
Time
(hours)
288
Faecal streptococcus
nil
8
48
72
96
Results from all six studies confirmed Arglaes’
antimicrobial activity against the pathogens
commonly associated with wound infections.7
Pathogens tested included Staphylococcus
Greater than 90% reduction in viable
bacterial numbers after 48 hours.
0
to test the in vitro activity of controlled-release
controlled-release compound.7
Greater than 90% reduction in viable
bacterial numbers after 48 hours.
8
Six separate experiments have been completed
Arglaes and adhesive that also contains a
Escherichia coli
0
Illustrations shown here are representations of sustained-activity antimicrobial barrier effect.
8
Time
(hours)
Anti mi c r o bi al A c t i v i t y
Time
(hours)
288
aureus, Escherichia coli and Faecal
streptococcus.7
Independent study performed by Wickham Laboratories Limited, Hampshire, England
4
Powerful antimicrobial activity-up to 6 logs of reduction (in vitro studies)
5
THE t e c h n o lo gy b e h i n d A r g l a e s
S-SSI RATES AT 3 MONTHS6
22% REDUCTION
6
5.4%
5
Medline has long been an innovator in silver dressing
In one study, a hospital realized a 22 percent decrease
technology, with more unique application methods
in its overall sternal SSI (S-SSI) rate after implementing
to utilize the antibacterial properties of ionic silver
Arglaes Film as the standard of care for sternotomy
in wound dressings than any other company. When
incisions. Sternal SSI rates for the following nine-month
Arglaes Film was introduced in 1997, it was the first
period showed a continuation in the study results. 6
2
Arglaes is available as a transparent film dressing, with
1
6
Without
Arglaes
4.6%
With
Arglaes
4
3.6%
3
antimicrobial, sustained-release dressing on the market.
Arglaes technology utilizes ionic silver to create an
and without an alginate pad, as well as a powder. The
environment that is hostile to bacteria and fungi yet
film has a high moisture vapor transmission rate (MVTR)
completely non-cytotoxic. Arglaes’ sustained-activity
to help maintain an ideal moist wound environment.
0
FY99 Total
Jan-Mar
1999
ARGLAES FILM MSC9169
being applied
Jan-Mar
2000
ionic silver maintains full efficacy for up to seven days.
Sustained Release7
10,000,000
1,000,000
100,000
10,000
1,000
100
Numbers of
10
viable bacteria
I l l us t rat ion of C on t r ol l e d - Rel ea se Polymers
Arglaes provides an antimicrobial barrier for up to seven days. Silver ions are released at a constant rate, providing a barrier
that inhibits the growth of new bacteria and helps prevent the migration of already-existing bacteria.
24 HRS
48 HRS
7 DAYS
Staphylococcus aureus
Greater than 90% reduction in viable
bacterial numbers after 48 hours.
nil
0
10,000,000
1,000,000
100,000
10,000
1,000
100
Numbers of
10
viable bacteria
48
72
96
288
nil
10,000,000
1,000,000
100,000
10,000
1,000
100
Numbers of
10
viable bacteria
48
72
96
Time
(hours)
288
Faecal streptococcus
nil
8
48
72
96
Results from all six studies confirmed Arglaes’
antimicrobial activity against the pathogens
commonly associated with wound infections.7
Pathogens tested included Staphylococcus
Greater than 90% reduction in viable
bacterial numbers after 48 hours.
0
to test the in vitro activity of controlled-release
controlled-release compound.7
Greater than 90% reduction in viable
bacterial numbers after 48 hours.
8
Six separate experiments have been completed
Arglaes and adhesive that also contains a
Escherichia coli
0
Illustrations shown here are representations of sustained-activity antimicrobial barrier effect.
8
Time
(hours)
Anti mi c r o bi al A c t i v i t y
Time
(hours)
288
aureus, Escherichia coli and Faecal
streptococcus.7
Independent study performed by Wickham Laboratories Limited, Hampshire, England
4
Powerful antimicrobial activity-up to 6 logs of reduction (in vitro studies)
5
A r g l a e s IN THE O P ER ATING ROOM
in dications
· Surgical wounds
Arglaes Film and Arglaes Island offer protection to post-operative
incision sites by providing a barrier that inhibits the growth of new
bacteria and helps prevent the migration of already-existing bacteria
for a period of up to seven days.
· Donor sites
· Grafted wounds (Arglaes Powder only)
ARGLAES FILM MSC9314
being applied on a sternal incision
· Central lines, CVPS and PICC lines
(Arglaes Film only)
· Partial- and full-thickness wounds
Arglaes post-op dressings can be used over any
· Sutures
· Steri-strips
· Surgical adhesive
ARGLAES ISLAND MSC9145
Arglaes Island applied on a minimally
invasive incision for saphenous vein
harvesting
“I highly recommend using Arglaes
antimicrobial silver barrier dressings for
any program addressing post-op sites.”
—Rafael Concepcion, Associate Nurse Manager
Adult & Pediatric Cardiothoracic
Surgery & Transplant
Vascular & Endovascular Surgery
Jackson Memorial Hospital, Miami, Fla.
6
C HANGE FREQUENCY
· Staples
C on tra in dication s
routine form of surgical wound closure, including:
· Third-degree burns
· Patients with a known sensitivity to silver
· As a surgical implant (Arglaes Powder)
· Do not use topical antibiotics in conjunction
with Arglaes Powder
ARGLAES FILM MSC9314
being applied on a sternal incision
Arglaes Film: May be left in place for up to seven days
Arglaes Island & Arglaes Powder: May be left in place
for up to five days
Dressing change frequency will depend on the amount
of exudate.
ARGLAES FILM MSC9314
applied to a sternal incision
7
A r g l a e s IN THE O P ER ATING ROOM
in dications
· Surgical wounds
Arglaes Film and Arglaes Island offer protection to post-operative
incision sites by providing a barrier that inhibits the growth of new
bacteria and helps prevent the migration of already-existing bacteria
for a period of up to seven days.
· Donor sites
· Grafted wounds (Arglaes Powder only)
ARGLAES FILM MSC9314
being applied on a sternal incision
· Central lines, CVPS and PICC lines
(Arglaes Film only)
· Partial- and full-thickness wounds
Arglaes post-op dressings can be used over any
· Sutures
· Steri-strips
· Surgical adhesive
ARGLAES ISLAND MSC9145
Arglaes Island applied on a minimally
invasive incision for saphenous vein
harvesting
“I highly recommend using Arglaes
antimicrobial silver barrier dressings for
any program addressing post-op sites.”
—Rafael Concepcion, Associate Nurse Manager
Adult & Pediatric Cardiothoracic
Surgery & Transplant
Vascular & Endovascular Surgery
Jackson Memorial Hospital, Miami, Fla.
6
C HANGE FREQUENCY
· Staples
C on tra in dication s
routine form of surgical wound closure, including:
· Third-degree burns
· Patients with a known sensitivity to silver
· As a surgical implant (Arglaes Powder)
· Do not use topical antibiotics in conjunction
with Arglaes Powder
ARGLAES FILM MSC9314
being applied on a sternal incision
Arglaes Film: May be left in place for up to seven days
Arglaes Island & Arglaes Powder: May be left in place
for up to five days
Dressing change frequency will depend on the amount
of exudate.
ARGLAES FILM MSC9314
applied to a sternal incision
7
HO W A r g l a e s I S DI F F ERENT
Man ag e s b a c t e r ia l b u r d e n
No kn own resista n ce
Arglaes is effective against a broad spectrum of bacteria
No medically relevant bacteria have shown any
and fungi, including MRSA, VRE and E. coli. It also acts
resistance to ionic silver, including MRSA and VRE.
A DDITION A L A r g l a e s U S E S
Ar g laes on li n e s i t es
Arglaes Film provides an easy-to-
as a physical barrier to potentially dangerous bacteria.
Create s an ideal
use and effective barrier to bacteria
P r o v i d es c o n s ta n t
wou n d- hea l in g en v iron men t
at line sites. Simply apply as you
ant i m i cr o b ia l p r o t e c t io n
Arglaes applies the principles of moist wound healing to
would a transfer film. Arglaes contains
The sustained-activity ionic silver maintains its full
create an ideal environment for the body to heal itself.
controlled-release silver, inhibiting the
efficacy for up to seven days.
The dressings also help protect periwound skin from
growth of bacteria and fungi for up to
maceration.
N o n - cy t ot o x ic
ARGLAES POWDER MSC9210
Small amounts of non-cytotoxic controlled-release silver
Hel ps to i mprove
ions are present in the dressing, providing a barrier to
patien t comfort a n d mobil ity
bacteria and fungi without harming healthy tissue.
Arglaes dressings are comfortable. Patients can
Ar g laes In WOUND CARE
even shower without compromising the dressings’
Any size. Any shape. Any depth. No matter the size,
effectiveness.
use Arglaes Powder for difficult-to-dress wounds.
Ex t e nde d w e a r t im e
seven days.
Arglaes remains effective for up to seven days. This
extended wear time also helps to protect wounds from
Utilizing controlled-release polymers, Arglaes Powder
the trauma of frequent dressing changes.
provides a continuous level of antimicrobial silver ions
protecting the wound bed for a period of up to five
R e duce d c os t s
days.
Fewer dressing changes can translate to decreased
supply costs and time savings for your staff.
Arglaes Powder contains alginate to aid in fluid
ARGLAES FILM MSC9045
applied on a line site
handling. As the powder mixes with wound exudate,
it turns into a gel that adheres to the wound bed and
(MSC9023 can also be used to protect line sites)
is easily removed during wound irrigation.
8
9
HO W A r g l a e s I S DI F F ERENT
Man ag e s b a c t e r ia l b u r d e n
No kn own resista n ce
Arglaes is effective against a broad spectrum of bacteria
No medically relevant bacteria have shown any
and fungi, including MRSA, VRE and E. coli. It also acts
resistance to ionic silver, including MRSA and VRE.
A DDITION A L A r g l a e s U S E S
Ar g laes on li n e s i t es
Arglaes Film provides an easy-to-
as a physical barrier to potentially dangerous bacteria.
Create s an ideal
use and effective barrier to bacteria
P r o v i d es c o n s ta n t
wou n d- hea l in g en v iron men t
at line sites. Simply apply as you
ant i m i cr o b ia l p r o t e c t io n
Arglaes applies the principles of moist wound healing to
would a transfer film. Arglaes contains
The sustained-activity ionic silver maintains its full
create an ideal environment for the body to heal itself.
controlled-release silver, inhibiting the
efficacy for up to seven days.
The dressings also help protect periwound skin from
growth of bacteria and fungi for up to
maceration.
N o n - cy t ot o x ic
ARGLAES POWDER MSC9210
Small amounts of non-cytotoxic controlled-release silver
Hel ps to i mprove
ions are present in the dressing, providing a barrier to
patien t comfort a n d mobil ity
bacteria and fungi without harming healthy tissue.
Arglaes dressings are comfortable. Patients can
Ar g laes In WOUND CARE
even shower without compromising the dressings’
Any size. Any shape. Any depth. No matter the size,
effectiveness.
use Arglaes Powder for difficult-to-dress wounds.
Ex t e nde d w e a r t im e
seven days.
Arglaes remains effective for up to seven days. This
extended wear time also helps to protect wounds from
Utilizing controlled-release polymers, Arglaes Powder
the trauma of frequent dressing changes.
provides a continuous level of antimicrobial silver ions
protecting the wound bed for a period of up to five
R e duce d c os t s
days.
Fewer dressing changes can translate to decreased
supply costs and time savings for your staff.
Arglaes Powder contains alginate to aid in fluid
ARGLAES FILM MSC9045
applied on a line site
handling. As the powder mixes with wound exudate,
it turns into a gel that adheres to the wound bed and
(MSC9023 can also be used to protect line sites)
is easily removed during wound irrigation.
8
9
P ROD U CT IN F ORM ATION
ARGLAES FILM
MSC9314
P ROD U CT IN F ORM ATION
A r gl a e s
Bo r der ed Gauze
Controlled-release, ionic silver for antimicrobial protection.
A water-resistant, easy-to-use secondary dressing.
Item No.
Description
Packaging
Item No.
Description
MSC9023
3
Film, 2 /8” x 3 /8” (6 x 8 cm).............................10/bx, 100/cs
MSC3222
2” x 2” (5 x 5 cm)............. 15/bx, 10 bx/cs
MSC9045
Film, 4” x 4 ¾” (10 x 12 cm).............................10/bx, 100/cs
MSC3244
4” x 4” (10 x 10 cm)......... 15/bx, 10 bx/cs
MSC9069
Film, 4 3/4” x 10” (12 x 25 cm)...........................10/bx, 50/cs
MSC3245
4” x 5” (10 x 13 cm)......... 15/bx, 10 bx/cs
MSC9314
Film, 3” x 14” (8 x 36 cm), post-op style..........10/bx, 50/cs
MSC3248
4” x 8” (10 x 20 cm)......... 15/bx, 10 bx/cs
MSC3266
6” x 6” (15 x 15 cm)......... 15/bx, 10 bx/cs
MSC32410
4” x 10” (10 x 25 cm)....... 15/bx, 10 bx/cs
MSC32414
4” x 14” (10 x 36 cm)....... 15/bx, 10 bx/cs
1
3
1
Alginate Island, 2 /8” x 3 /8” (6 x 8 cm)............10/bx, 100/cs
MSC9123
MSC9145
Alginate Island, 4” x 4 ¾” (10 x 12 cm)............10/bx, 100/cs
MSC9169
Alginate Island, 4 ¾” x 10” (12 x 25 cm)..........10/bx, 50/cs
MSC9205
Powder, 5 gm bottle.........................................5/bx, 20/cs
MSC9210
Powder, 10 gm bottle.......................................5/bx, 20/cs
BORDERED GAUZE
MSC3222
Packaging
Str ataso r b ®
A convenient, waterproof secondary dressing.
ARGLAES POWDER
MSC9205
Maxorb
®
Extra
STRATASORB
MSC3044
Fast-acting absorption without lateral wicking.
Item No.
IItem No.
Description
Packaging
MSC3044
4” x 4” (10 x 10 cm)......... 10/bx, 10 bx/cs
MSC3066
6” x 6” (15 x 15 cm)......... 10/bx, 10 bx/cs
MSC3068
6” x 7.5” (15 x 19 cm)...... 10/bx, 10 bx/cs
MSC30410
4” x 10” (10 x 25 cm)....... 10/bx, 10 bx/cs
MSC30414
4” x 14” (10 x 36 cm)....... 10/bx, 10 bx/cs
Description..................................................Packaging
MSC7112EP 1” x 12” (2.5 x 30 cm), post-op rope................5/bx, 20/cs
MAXORB EXTRA
MSC7112EP
Opt if o a m ® AG + Post- Op Strips
A transparent film dressing with an absorbent silver foam
pad. This post-op dressing has ionic silver technology
as well, but utilizes a non-adherent foam rather than the
adhesive on the film.
OPTIFOAM AG STRIP
MSC96316
10
Item No.
Description
Packaging
MSC96316
Film, 3” x 16” (8 x 41 cm).................................10/bx, 100/cs
ARGLAES ISLAND MSC9169 being applied on a sternal incision
11
P ROD U CT IN F ORM ATION
ARGLAES FILM
MSC9314
P ROD U CT IN F ORM ATION
A r gl a e s
Bo r der ed Gauze
Controlled-release, ionic silver for antimicrobial protection.
A water-resistant, easy-to-use secondary dressing.
Item No.
Description
Packaging
Item No.
Description
MSC9023
3
Film, 2 /8” x 3 /8” (6 x 8 cm).............................10/bx, 100/cs
MSC3222
2” x 2” (5 x 5 cm)............. 15/bx, 10 bx/cs
MSC9045
Film, 4” x 4 ¾” (10 x 12 cm).............................10/bx, 100/cs
MSC3244
4” x 4” (10 x 10 cm)......... 15/bx, 10 bx/cs
MSC9069
Film, 4 3/4” x 10” (12 x 25 cm)...........................10/bx, 50/cs
MSC3245
4” x 5” (10 x 13 cm)......... 15/bx, 10 bx/cs
MSC9314
Film, 3” x 14” (8 x 36 cm), post-op style..........10/bx, 50/cs
MSC3248
4” x 8” (10 x 20 cm)......... 15/bx, 10 bx/cs
MSC3266
6” x 6” (15 x 15 cm)......... 15/bx, 10 bx/cs
MSC32410
4” x 10” (10 x 25 cm)....... 15/bx, 10 bx/cs
MSC32414
4” x 14” (10 x 36 cm)....... 15/bx, 10 bx/cs
1
3
1
Alginate Island, 2 /8” x 3 /8” (6 x 8 cm)............10/bx, 100/cs
MSC9123
MSC9145
Alginate Island, 4” x 4 ¾” (10 x 12 cm)............10/bx, 100/cs
MSC9169
Alginate Island, 4 ¾” x 10” (12 x 25 cm)..........10/bx, 50/cs
MSC9205
Powder, 5 gm bottle.........................................5/bx, 20/cs
MSC9210
Powder, 10 gm bottle.......................................5/bx, 20/cs
BORDERED GAUZE
MSC3222
Packaging
Str ataso r b ®
A convenient, waterproof secondary dressing.
ARGLAES POWDER
MSC9205
Maxorb
®
Extra
STRATASORB
MSC3044
Fast-acting absorption without lateral wicking.
Item No.
IItem No.
Description
Packaging
MSC3044
4” x 4” (10 x 10 cm)......... 10/bx, 10 bx/cs
MSC3066
6” x 6” (15 x 15 cm)......... 10/bx, 10 bx/cs
MSC3068
6” x 7.5” (15 x 19 cm)...... 10/bx, 10 bx/cs
MSC30410
4” x 10” (10 x 25 cm)....... 10/bx, 10 bx/cs
MSC30414
4” x 14” (10 x 36 cm)....... 10/bx, 10 bx/cs
Description..................................................Packaging
MSC7112EP 1” x 12” (2.5 x 30 cm), post-op rope................5/bx, 20/cs
MAXORB EXTRA
MSC7112EP
Opt if o a m ® AG + Post- Op Strips
A transparent film dressing with an absorbent silver foam
pad. This post-op dressing has ionic silver technology
as well, but utilizes a non-adherent foam rather than the
adhesive on the film.
OPTIFOAM AG STRIP
MSC96316
10
Item No.
Description
Packaging
MSC96316
Film, 3” x 16” (8 x 41 cm).................................10/bx, 100/cs
ARGLAES ISLAND MSC9169 being applied on a sternal incision
11
OR TA B LE & S TRETC HER PAD S
STERILLIU M ®
Prevention is key. Medline’s pressure redistribution
Sterillium Rub’s high alcohol content delivers a
stretcher pads and operating room table pads can
devastating blow to microorganisms – not your
help redistribute pressure before, during and after
skin. Its balanced emollient blend leaves hands
surgery.
feeling soft and smooth, never greasy or sticky,
and makes gloving a breeze. But that doesn’t
mean that Sterillium Rub makes any sacrifices in
efficacy!
Medline Industries, Inc.
One Medline Place
Mundelein, IL 60060
12
Medline United States
1-800-MEDLINE (633-5463)
www.medline.com
Medline Canada
1-800-396-6996
www.medline.ca | [email protected]
Medline México S. De R.L De C.V.
01-800-831-0898
www.medline.mexico |
[email protected]
©2009 Medline Industries, Inc.
We reserve the right to correct any errors that may
occur within this brochure.
Not all products are currently available for sale in
Canada. Please contact your Account Representative
for additional information.
Not all products are currently available for sale in
Mexico. Please contact your Account Representative
for additional information.
Medline, Optifoam, Maxorb and Stratasorb are registered trademarks of Medline Industries, Inc. Sterillium is a registered trademark of Bode-Chemie
GmbH. Arglaes is a registered trademark of Giltech Limited Corporation.
MKT209096/LIT315R/10M/TKZ/13